For years multi-national pharma companies have enjoyed a relatively stable tax rate. Now PriceWaterhouseCoopers says that as personalized medicines grow in importance, the life sciences industry will become more service-oriented, adding diagnostics and new patient compliance technology that is likely to drive a rise in their overall tax rate -- a trend that could have serious consequences for the biotech companies Big Pharma partners with to develop a new generation of biologics. Report